Navigation Links
Lenalidomide, Granted Approval by FDA to Join Multiple Myeloma Drugs

Graham Burton, M.D., SVP, Regulatory Affairs and Pharmacovigilance said that FDA’s approval of REVLIMID (lenalidomide) offered a new oral drug option// to the group of people suffering from multiple myeloma.

Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has granted approval for its Supplemental New Drug Application (sNDA) for an additional indication for REVLIMID (lenalidomide), for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. REVLIMID is also approved for use in the treatment of patients with transfusion-dependent anemia due to Low-or- Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Multiple myeloma is the second most common blood cancer in the United States, affecting approximately 50,000 people. About 14,600 new cases of multiple myeloma are diagnosed each year and about 12,000 Americans are expected to die of multiple myeloma in 2006. In the REVLIMID (lenalidomide)/dexamethasone treatment group, 151 patients (45%) underwent at least one dose interruption with or without a dose reduction of REVLIMID (lenalidomide) compared to 21% in the placebo/dexamethasone treatment group. Most adverse events and Grade 3 or 4 adverse events were more frequent in patients who received the combination of REVLIMID (lenalidomide)/dexamethasone compared to placebo /dexamethasone.

‘The FDA approval of REVLIMID offers a new oral therapeutic option to this particular group of patients with multiple myeloma,’ said Graham Burton, M.D., SVP, Regulatory Affairs and Pharmacovigilance for Celgene. REVLIMID will be available in the following strengths: 5 mg, 10 mg, 15 mg, and 25 mg capsules.

Source: Eurekaler
'"/>




Page: 1

Related medicine news :

1. Bail Granted To The Doctor Despite Her Patients Death
2. Azerbaijan Granted 5 million dollars in Fight Against Bird Flu
3. Developer Of Vaccine For Cancer Granted A Prestigious Fellowship
4. American Senior Citizens Granted More Time
5. Numerous Defense Personnel Granted Early Retirement Due to Mental Illness
6. Approval for DNA test to detect cystic fibrosis
7. Vaccine For Cervical Cancer Awaits Approval
8. WHO Gives Its Approval For Bird Flu Test Kit
9. FDA Gives Its Approval For Inhaler
10. RotaTeq Gets US Approval
11. Better Communication With FDA Could Speed Up Approval Of New Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... ... They are musicians and librarians, fashion designers and fitness instructors, actors, athletes and ... around the nation. What do they have in common? All have been affected by ... new photographic exhibit debuting Friday, December 9 at Logan International Airport in Boston. , ...
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on ... later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his ... the hospital’s 30th heart transplant recipient. , “He was playing at home, when we ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... connectors, is now promoting to the US market its advanced highly customizable contact ... and ODU TURNTAC®. These advanced technologies are ideal for a wide range ...
(Date:12/7/2016)... MI (PRWEB) , ... December 07, 2016 , ... ... and financial consultation services from offices located in South Lyon, Dewitt, Williamston, East ... benefit a basketball coach who needs treatment for a brain tumor. , Jason ...
(Date:12/7/2016)... Folsom, CA (PRWEB) , ... December 07, 2016 ... ... that provides insurance and financial consultation services to residents in the Sacramento/Folsom region, ... Choice Another Chance treatment facility. , The Another Choice Another Chance treatment center ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Dec. 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ... present a company overview at the BMO Capital Markets Prescriptions for ... York, NY . A live webcast of the ... the Ionis website.  The replay will be available within 48 hours ... ...
(Date:12/7/2016)... 7, 2016 Today, Stock-Callers.com presents four ... JAZZ ), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH ... AveXis Inc. (NASDAQ: AVXS ). From its peak ... 37% to reach a level equal to what it saw ... approximately 14% for the year, it has still out-performed other ...
(Date:12/7/2016)... According to the latest market ... Study on Multiplex Detection Immunoassay: North America to Dominate ... detection immunoassay market is expected to witness a CAGR of ... ...      (Logo: http://photos.prnewswire.com/prnh/20161114/438683LOGO) ...
Breaking Medicine Technology: